Author: admin

Swiss based Inacta Ventures and The Hashgraph Association Co-Host Morocco WEB3FEST GITEX Edition

Swiss based Inacta Ventures and The Hashgraph Association Co-Host Morocco WEB3FEST GITEX Edition

Marrakech, Morocco – April 7th, 2025 – Morocco WEB3FEST GITEX Edition, a global conference series focused on technology and innovation in AI, Blockchain, and sustainability, organized by Inacta Ventures and co-hosted by The Hashgraph Association, being carried out in Marrakech, Morocco from April 14th – 16th 2025 is set to bring together the world’s foremost Web3 leaders, innovators, and investors at the intersection of technology, finance, and sustainability.

Hosted in Marrakech during GITEX Africa, this premier event serves as a critical bridge linking the vibrant ecosystems of Africa, the Middle East, and Europe. With a strong commitment to advancing decentralized technologies and sustainable innovation, Morocco WEB3FEST GITEX Edition is poised to drive meaningful dialogue and collaboration among industry pioneers, enterprises, and policymakers.

What is the WEB3FEST?

WEB3FEST is a global conference series focused on technology and innovation in AI, Blockchain and Sustainability. It serves as a vibrant hub where companies across the value chain – from agile startups to international corporations – converge to share ideas, build networks, and shape the future of the industry.

Kamal Youssefi – President of The Hashgraph Association noted, “We are honored to be co-hosting the WEB3FEST in Morocco during GITEX Africa given that one of the aims of THA is to empower entrepreneurs, enterprises and governments with the technologies and knowhow needed to foray into Web3 while keeping sustainability at the heart of their endeavors. This is why Hedera network, considered one of the most sustainable in the world, is at the center of our conversations.”

Ralf Glabischnig – Founder of Inacta Ventures, added, “Switzerland has always been a hub for Blockchain innovation, and our Layer 1 technology is solving real-world challenges in developing countries. With Morocco as the perfect gateway to Africa, we are connecting European expertise with Africa’s immense potential for Blockchain adoption.”

Event Highlights:

The Green Block Talks

April 14th, 2025

Sofitel Marrakech Palais Imperial

A high-impact evening bringing together thought leaders and industry experts to discuss the role of AI and Web3 in driving sustainability. Featuring insightful panels, networking opportunities, and meaningful discussions.

Featured Speakers:

  • Ian Putter – Head of Blockchain COE, Standard Bank
  • Tom Rieder – Director Marketplace, The Green Block
  • Abdelaziz Benyahya – Chief Transformation Officer, AXA Morocco
  • Kamal Youssefi – President of The Board, The Hashgraph Association
  • Ralf Glabischnig – Founder, Inacta Ventures


WEB3 Investor Dinner (Co-hosted by NEOAI)

April 15th, 2025

Private Villa, Marrakech

An exclusive, invitation-only gathering for venture capitalists, fund managers, and private equity professionals. This intimate setting will facilitate high-level discussions on investment opportunities, portfolio strategies, and the evolving digital asset landscape.

About the Organizer Inacta Ventures

At the helm of the WEB3 revolution, Inacta Ventures builds ecosystems, ventures, and smart capital strategies. With operations in the thriving Crypto Valley in Switzerland and the Crypto Oasis in the UAE, Inacta empowers over 100 portfolio companies and enterprises to scale groundbreaking WEB3 solutions.

About the Co-Host The Hashgraph Association

The Hashgraph Association, a Swiss non-profit, drives global adoption of Hedera-powered solutions by funding innovation, training, and venture programs. It promotes economic inclusion and a digital future with a positive ESG impact. https://www.hashgraph.swiss/about

Registration

Reserve your spot now and join the world’s brightest minds to shape the future of WEB3: Register Here

For more details, visit: web3fest.ch

Contact:

Fabio Schlaf

Head of Ecosystem Development

Inacta Ventures & Crypto Oasis

fabio.schlaf@inactaventures.com

Media Contact
Company Name: Plato Data Intelligence
Contact Person: Bryan Feinberg
Email: Send Email
Phone: +1551 574-2169
Address:144 E 44th Street
City: New York
State: New York
Country: United States
Website: platodata.io

Aura Concrete And Landscape Enhancing Outdoor Spaces in North Canton

Aura Concrete And Landscape Enhancing Outdoor Spaces in North Canton
Aura Concrete and Landscape continues to transform outdoor spaces in North Canton with high-quality concrete and landscaping solutions. A company committed to craftsmanship and innovation, provides durable, aesthetically appealing surfaces that enhance residential and commercial properties. Specializing in custom concrete work, decorative patios, and complete landscape solutions, the company offers functional and visually striking designs tailored to each project’s unique needs.

Elevating Outdoor Living With Expert Concrete Services

Well-designed outdoor spaces add value and functionality to any property. Expertly crafted concrete surfaces, from driveways to patios and walkways, provide durability and curb appeal. Aura Concrete and Landscape offers a range of custom solutions, utilizing high-quality materials and advanced techniques to create lasting results.

Through detailed planning and precision installation, the company helps property owners achieve both practical and artistic goals. Whether the focus is on enhancing curb appeal or creating a welcoming backyard retreat, the right concrete features can make a significant impact.

Among the company’s specialties, stamped concrete patio North Canton designs have become a sought-after solution for homeowners looking to achieve the beauty of natural stone, brick, or wood while maintaining the strength and longevity of concrete. These patios combine artistry with durability, making them a practical yet elegant addition to any home.

Reliable Concrete Solutions for Residential and Commercial Properties

With years of expertise in the industry, Aura Concrete And Landscape ensures that every project meets high standards of craftsmanship. Each installation is completed with careful attention to structural integrity, ensuring that surfaces remain strong and resilient over time.

As a leading concrete contractor North Canton, the company offers a variety of services, including driveway installations, decorative patios, stamped concrete, and foundation work. Commercial property owners also benefit from customized solutions that improve functionality while enhancing the overall appearance of their spaces.

Beyond aesthetics, properly installed concrete solutions contribute to long-term cost savings. By using durable materials and expert construction methods, property owners can enjoy low-maintenance surfaces designed to withstand harsh weather conditions and daily use.

Comprehensive Concrete and Landscaping Services

A well-balanced outdoor space requires more than just concrete installations. Aura Concrete And Landscape provides complete design and landscaping solutions that integrate seamlessly with newly installed hardscapes.

Through concrete services North Canton, property owners can achieve a cohesive look that enhances both functionality and beauty. Whether the goal is to install a new patio, upgrade a driveway, or create a complete outdoor living area, the company delivers results that stand the test of time.

Tailored Designs to Match Any Style

Every property is unique; outdoor spaces should reflect individual preferences and functional needs. Aura Concrete and Landscape works closely with clients to develop customized solutions that align with specific styles and requirements. Various finishes and patterns, from traditional designs to modern aesthetics, are available to create a personalized look.

Stamped and decorative concrete solutions allow the replicating high-end materials at a more affordable price point. With numerous textures, colors, and patterns to choose from, each project is crafted to blend seamlessly with the surrounding environment.

About Aura Concrete And Landscape

Aura Concrete And Landscape is a premier high-quality concrete and landscaping solution provider in North Canton, OH. Specializing in decorative concrete, stamped patios, and comprehensive outdoor design services, the company is dedicated to delivering durable, visually appealing results. By combining expert craftsmanship with innovative techniques, Aura Concrete And Landscape helps property owners create functional and stylish outdoor spaces that enhance the beauty and value of their properties.

Media Contact
Company Name: Aura Concrete And Landscape
Contact Person: Brian Pittman
Email: Send Email
Phone: (330) 575-6682
Address:12497 Chestnut St NW
City: Canal Fulton
State: OH
Country: United States
Website: www.Auralandscapes.com

British Dental Revolutionizes High-Quality Dental Care for French Patients in Bucharest

Bucharest, Romania – In a healthcare landscape where affordability and excellence rarely coexist, the Clinique Franco-Britannique de Bucarest – British Dental – emerges as a leading solution for French-speaking patients seeking high-level dental care at fair prices. Located just 2.5 hours by plane from Paris, British Dental is setting a new standard in dental tourism by combining cutting-edge technology, French-speaking assistance, and internationally certified dental professionals — all while offering up to 50% savings on treatment costs.

A European Gem for Dental Tourism

As more patients in France, Belgium, and Switzerland express concern about the rising costs of local dental services and the unreliable quality of low-cost centers, British Dental offers an ethical, safe, and technologically advanced alternative — without the hidden fees or language barriers.

British Dental is not just another dental clinic abroad; it is a certified center of excellence, affiliated with the Straumann Group, ISO 9001 certified, and ranked 37th among the world’s top clinics by GCR (Global Clinic Rating). Moreover, it is the clinic recommended by both the British and French embassies, a mark of trust that speaks volumes.

A Fully French-Speaking Experience

Understanding the needs of French patients is at the heart of the British Dental experience. The clinic offers:

  • Pre-operative consultations in France, ensuring that patients can begin their treatment journey with confidence.

  • Follow-up care in France post-surgery, eliminating common hesitations about post-treatment management.

  • A dedicated French-speaking coordination team that supports every step of the journey — from first contact to follow-up care.

This fully bilingual service removes one of the biggest barriers for international care: communication. Patients are never left guessing or alone at any stage.

Treatments That Transform Lives

The Clinique Franco-Britannique de Bucarest is renowned for full-mouth restorations — complex cases where patients undergo life-changing transformations. These treatments typically include:

  • Implantology (All-on-4 / All-on-6)

  • Crowns and bridges

  • Facial aesthetics with veneers

  • Inlays, onlays, and bone grafting

Thanks to advanced digital technologies, including CEREC CAD/CAM, 3D imaging, and 4D jaw tracking (MODJAW), treatments are more precise, less invasive, and faster than ever. Many patients receive non-removable provisional teeth from the first visit, minimizing discomfort and improving confidence from day one.

Quality Over Quantity: The Anti-Low-Cost Model

British Dental distinguishes itself from typical “low-cost” clinics through its commitment to safety, ethics, and long-term results. The reduced cost isn’t about cutting corners — it’s about operational efficiency. Lower local operational costs in Romania allow the clinic to offer premium care at competitive prices.

Patients benefit from:

  • World-class care at 50–70% lower prices than in France.

  • French Social Security and mutual insurance reimbursements.

  • Fewer trips and fewer appointments due to streamlined treatment processes.

As a result, British Dental patients report significant savings without sacrificing materials, professionalism, or comfort.

The British Dental Experience: What Patients Say

From retired surgeons to everyday patients, testimonials paint a picture of exceptional results and human-centered care:

“Chirurgien à la retraite, je suis venu me faire poser ici des implants. Je suis très satisfait de la très haute technicité de la clinique.”

“Cela a pris quelques mois, mais j’ai retrouvé mon sourire et je vais pouvoir sourire à la vie!”

“L’accueil en Roumanie est excellent, les gens sont très gentils, et les dentistes très compétents!”

These are just a few voices among hundreds of satisfied patients who have rediscovered their confidence, health, and joy through the care provided at British Dental.

A Streamlined Journey: From Consultation to Completion

The clinic has built a comprehensive, step-by-step process that guides patients through a stress-free treatment journey:

  1. Initial Contact Patients submit an online form on https://british.dental to start the conversation.

  2. Diagnostic Phase The clinic’s medical team provides a prescription for a dental X-ray or CT scan.

  3. Customized Quote and Treatment Plan Based on the patient’s results, a detailed, transparent quote is provided, including optional treatment paths.

  4. Travel and Treatment Once the plan is confirmed, patients travel to Bucharest, where treatments begin in the state-of-the-art clinic.

  5. Post-Treatment Follow-Up After their stay, patients receive ongoing support and follow-up appointments in France.


A New Way to Smile in Bucharest

Patients often discover more than just great dental care during their visit. Bucharest itself surprises visitors with its green spaces, calm atmosphere, and rich cultural scene. British Dental patients often blend their medical journey with an enriching travel experience, returning home not just with a healthier smile, but also beautiful memories.

Message from the Founder: Dr. Cosmin Teasdale

“Ma vision pour la BBDP est de dépasser les normes traditionnelles de dentisterie. Nous visons l’excellence, en garantissant un diagnostic précis et un traitement sur-mesure… Ne comparez pas uniquement les prix, mais aussi l’éthique, la précision et l’excellence.”

Dr. Cosmin Teasdale’s leadership has made British Dental a pioneer in precision dentistry. The clinic is not only equipped with digital impressions, intraoral scanners, and its own dental lab, but also committed to constant innovation and ethical practices.

Transparency, Ethics, and Excellence at Every Step

  • No intermediaries or hidden agency fees – British Dental works directly with patients.

  • Same high-quality services, including travel assistance and French-speaking coordinators, at a lower cost.

  • A trusted team led by specialists with international certifications and continual training.

Whether you’re considering replacing a few teeth or undergoing a full-mouth restoration, British Dental ensures a smooth, transparent, and life-enhancing experience.

Ready to Begin Your Journey?

Get a no-obligation quote today: Visit https://british.dental or email office@british.dental

Media Contact
Company Name: British Dental
Email: Send Email
Phone: +40 744 488 812
City: Bucharest
Country: Romania
Website: https://british.dental

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: British Dental Revolutionizes High-Quality Dental Care for French Patients in Bucharest

Zenir Launches Sustainable Medical Uniforms Combining Style and Performance

Healthcare apparel brand on the rise introduces eco-friendly uniforms designed for modern professionals.

Zenir, an innovative medical apparel brand dedicated to sustainability and performance, announced today the launch of its premium line of medical uniforms and scrubs. Crafted from GRS-Certified sustainable materials, Zenir’s eco-friendly uniforms set a new standard in healthcare apparel by effectively balancing style, practicality, and environmental responsibility.

Zenir addresses a growing demand within the healthcare industry for uniforms that not only meet professional standards but also reflect a commitment to environmental sustainability. The brand’s apparel offers distinctive advantages such as moisture-wicking capabilities, ensuring comfort throughout demanding shifts. Additionally, Zenir uniforms feature anti-microbial properties to enhance hygiene by reducing germ proliferation, alongside built-in UV protection to shield professionals from harmful ultraviolet rays.

“At Zenir, we believe that looking good and doing good can go hand in hand,” stated a Zenir spokesperson. “Our commitment to using GRS-Certified sustainable materials means our uniforms don’t just perform exceptionally, they also contribute to a healthier planet. We’re excited to offer healthcare professionals a choice that supports both their well-being and the environment.”

Customer feedback has been overwhelmingly positive, highlighting both the functionality and ethical standards of the Zenir apparel line. Jessica Ruiz, an RN at Los Angeles Medical Center, commented, “I appreciate the thoughtful design and comfort of Zenir scrubs. Knowing that my uniform is sustainably made gives me confidence that I’m supporting responsible practices in healthcare. Zenir scrubs help me perform my best and feel good about my environmental impact.”

Zenir’s dedication to sustainability is integrated into every aspect of its business operations. From sourcing environmentally responsible materials to employing manufacturing processes that minimize ecological footprints, Zenir actively promotes practices beneficial for both people and the planet. With this new apparel line, the brand positions itself as a leader in the healthcare apparel industry, challenging conventional standards and paving the way for a more sustainable future.

Healthcare professionals interested in exploring Zenir’s sustainable uniform offerings can visit the brand’s website at https://www.shopzenir.com.

About Zenir

Zenir is a forward-thinking medical apparel brand focused on providing stylish, sustainable uniforms for healthcare professionals. Utilizing GRS-Certified eco-friendly materials, Zenir creates uniforms that combine performance, comfort, and environmental consciousness. By promoting sustainability within the healthcare sector, Zenir seeks to positively influence the industry’s future.

Media Contact
Company Name: Zenir
Contact Person: Admin
Email: Send Email
Country: United States
Website: https://www.shopzenir.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Zenir Launches Sustainable Medical Uniforms Combining Style and Performance

Ulcerative Colitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Ulcerative Colitis Pipeline Insight 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Ulcerative Colitis Treatment Landscape. Click here to read more @ Ulcerative Colitis Pipeline Outlook

Key Takeaways from the Ulcerative Colitis Pipeline Report

  • In April 2025, Merck Sharp & Dohme LLC announced a study 1’s primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at week 52. Study 2’s primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12.
  • In April 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
  • DelveInsight’s Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment.
  • The leading Ulcerative Colitis Companies such as Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
  • Promising Ulcerative Colitis therapies such as VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.

Discover groundbreaking developments in Ulcerative Colitis therapies! Gain in-depth knowledge of key Ulcerative Colitis clinical trials, emerging drugs, and market opportunities @ Ulcerative Colitis Clinical Trials Assessment

Ulcerative Colitis Emerging Drugs Profile

  • Obefazimod: Abivax

Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis.

  • ABBV-668: AbbVie

ABBV-668 is under development for the treatment of crohn’s disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.

  • TEV-48574: Teva Pharmaceutical

Anti-TL1A (TEV-’574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-’574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-’574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn’s disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-’574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.

  • SOR102: Sorriso Pharmaceuticals

SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis.

The Ulcerative Colitis Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.
  • Ulcerative Colitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market

Stay informed about the Ulcerative Colitis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Ulcerative Colitis Unmet Needs

Ulcerative Colitis Companies

Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.

Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Ulcerative Colitis Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Transform your understanding of the Ulcerative Colitis Pipeline! See the latest progress in drug development and clinical research @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspectives

Scope of the Ulcerative Colitis Pipeline Report

  • Coverage- Global
  • Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
  • Ulcerative Colitis therapies- VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.
  • Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

“Stay Ahead in Gastroenterology Research–Access the Full Ulcerative Colitis Pipeline Analysis Today! @ Ulcerative Colitis Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Ulcerative Colitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Ulcerative Colitis– DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Ulcerative Colitis Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. Mirikizumab: Eli Lilly and Company
  11. Drug profiles in the detailed report…..
  12. Late Stage Products (Phase III)
  13. Obefazimod: Abivax
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. ABBV-668: AbbVie
  17. Drug profiles in the detailed report…..
  18. Early Stage Products (Phase I)
  19. SOR102: Sorriso Pharmaceuticals
  20. Drug profiles in the detailed report…..
  21. Preclinical Stage Products
  22. Drug Name: Company Name
  23. Drug profiles in the detailed report…..
  24. Inactive Products
  25. Ulcerative Colitis Key Companies
  26. Ulcerative Colitis Key Products
  27. Ulcerative Colitis- Unmet Needs
  28. Ulcerative Colitis- Market Drivers and Barriers
  29. Ulcerative Colitis- Future Perspectives and Conclusion
  30. Ulcerative Colitis Analyst Views
  31. Ulcerative Colitis Key Companies
  32. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ulcerative Colitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Advanced Urothelial Carcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Advanced Urothelial Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Advanced Urothelial Carcinoma pipeline landscape. It covers the Advanced Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Urothelial Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Advanced Urothelial Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Advanced Urothelial Carcinoma Pipeline Outlook

Key Takeaways from the Advanced Urothelial Carcinoma Pipeline Report

  • In April 2025, Janssen Research & Development LLC conducted a study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with cetrelimab, and for erdafitinib in combination with cetrelimab and platinum (cisplatin and carboplatin) chemotherapy and; (b) to evaluate the safety and clinical activity of erdafitinib alone and in combination with cetrelimab in cisplatin-ineligible participants with metastatic or locally advanced urothelial cancer (UC) with select fibroblast growth factor receptor (FGFR) gene alterations and no prior systemic therapy for metastatic disease.
  • DelveInsight’s Advanced Urothelial Carcinoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Advanced Urothelial Carcinoma treatment.
  • The leading Advanced Urothelial Carcinoma Companies such as Merck Sharp & Dohme LLC, Evopoint Biosciences Inc., Exelixis, Tyra Biosciences, Inc., BeiGene, BicycleTx Limited, Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd., Nektar Therapeutics, Bayer, Abbisko Therapeutics Co., Ltd., Aurigene Discovery Technologies Limited, Adlai Nortye Biopharma Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd. and others.
  • Promising Advanced Urothelial Carcinoma Pipeline Therapies such as SHR-A2102, Adebrelimab injection, Selinexor, Pembrolizumab, 9MW2821, Toripalimab and others.

Stay ahead with the most recent pipeline outlook for Advanced Urothelial Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Advanced Urothelial Carcinoma Treatment Drugs

Advanced Urothelial Carcinoma Emerging Drugs Profile

  • 9MW2821: Mabwell (Shanghai) Bioscience Co., Ltd.

9MW2821 is a novel Nectin-4 targeting ADC developed by ADC platform and automated high-throughput antibody discovery platform of Mabwell. It boasts the advantages of homogenous structure, high purity and being easy production. It has also demonstrated favorable druggability properties in binding affinity, endocytosis, preliminary in vivo and in vitro pharmacodynamic activities, drug metabolism properties and preliminary safety. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Advanced Urothelial Carcinoma.

  • AZD4547: Abbisko Therapeutics Co, Ltd

AZD-4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Advanced Urothelial Carcinoma.

  • AUR106: Aurigene Discovery Technologies Limited

AUR106 is an orally bioavailable small molecule inhibitor of the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and the immunosuppressive ligand programmed cell death-1 ligand 1, with potential immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, TIGIT/PD-L1 inhibitor AUR-106 simultaneously targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream signaling pathways. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Advanced Urothelial Carcinoma.

The Advanced Urothelial Carcinoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Urothelial Carcinoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Urothelial Carcinoma Treatment.
  • Advanced Urothelial Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Advanced Urothelial Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Urothelial Carcinoma market

Explore groundbreaking therapies and clinical trials in the Advanced Urothelial Carcinoma Pipeline. Access DelveInsight’s detailed report now! @ New Advanced Urothelial Carcinoma Drugs

Advanced Urothelial Carcinoma Companies

Merck Sharp & Dohme LLC, Evopoint Biosciences Inc., Exelixis, Tyra Biosciences, Inc., BeiGene, BicycleTx Limited, Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd., Nektar Therapeutics, Bayer, Abbisko Therapeutics Co., Ltd., Aurigene Discovery Technologies Limited, Adlai Nortye Biopharma Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd. and others.

Advanced Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Advanced Urothelial Carcinoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Unveil the future of Advanced Urothelial Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Advanced Urothelial Carcinoma Market Drivers and Barriers

Scope of the Advanced Urothelial Carcinoma Pipeline Report

  • Coverage- Global
  • Advanced Urothelial Carcinoma Companies- Merck Sharp & Dohme LLC, Evopoint Biosciences Inc., Exelixis, Tyra Biosciences, Inc., BeiGene, BicycleTx Limited, Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd., Nektar Therapeutics, Bayer, Abbisko Therapeutics Co., Ltd., Aurigene Discovery Technologies Limited, Adlai Nortye Biopharma Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd. and others.
  • Advanced Urothelial Carcinoma Pipeline Therapies- SHR-A2102, Adebrelimab injection, Selinexor, Pembrolizumab, 9MW2821, Toripalimab and others.
  • Advanced Urothelial Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Urothelial Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Advanced Urothelial Carcinoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Advanced Urothelial Carcinoma Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Urothelial Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Urothelial Carcinoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. 9MW2821: Mabwell (Shanghai) Bioscience Co., Ltd.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. AZD4547: Abbisko Therapeutics Co, Ltd
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AUR106: Aurigene Discovery Technologies Limited
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Urothelial Carcinoma Key Companies
  21. Advanced Urothelial Carcinoma Key Products
  22. Advanced Urothelial Carcinoma- Unmet Needs
  23. Advanced Urothelial Carcinoma- Market Drivers and Barriers
  24. Advanced Urothelial Carcinoma- Future Perspectives and Conclusion
  25. Advanced Urothelial Carcinoma Analyst Views
  26. Advanced Urothelial Carcinoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Urothelial Carcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Influenza Pipeline Insight 2025” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Influenza pipeline landscape. It covers the Influenza pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Influenza therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Influenza Pipeline. Dive into DelveInsight’s comprehensive report today! @ Influenza Pipeline Outlook

Key Takeaways from the Influenza Pipeline Report

  • In April 2025, Eurofarma Laboratories S.A announced a phase 3, multicenter, Randomized, Double-blind, comparative clinical trial to evaluate the association of paracetamol 500mg + Fexofenadine 60mg + Phenylephrine 20mg in the flu and common cold treatment. A Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
  • DelveInsight’s Influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment.
  • The leading Influenza Companies such as Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others.
  • Promising Influenza Therapies such as OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others.

Stay ahead with the most recent pipeline outlook for Influenza. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Influenza Treatment Drugs

Influenza Emerging Drugs

  • mRNA-1010: Moderna

mRNA-1010 is a vaccine candidate that encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) for the prevention of influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. HA is a major influenza surface glycoprotein that is considered an important target to generate broad protection against influenza and is the primary target of currently available influenza vaccines. Currently, it is in Phase III stage of clinical trial evaluation to treat patients suffering from Seasonal Influenza.

  • SAB-176: SAB Biotherapeutics

SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate that leverages the human biological immune response in development for the treatment of hospitalized patients with severe seasonal influenza. The novel specifically targeted therapeutic generated from the company’s proprietary technology, the DiversitAb™ platform, is designed to specifically bind to Type A and Type B influenza viruses. Pre-clinical data suggests that SAB-176 offers potentially broad protection against diverse influenza strains. A highly-potent, polyclonal antibody therapy for severe seasonal influenza, could potentially treat severely ill patients and provide protective antibodies for high-risk populations, such as the elderly and immune compromised.

  • INNA-051: ENA Respiratory Pty Ltd

INNA-051 is a broad-spectrum antiviral immunomodulatory nasal spray under clinical development for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of severe complications. Based on its mechanism of action and intended route of administration, INNA-051 has the potential to address several viral respiratory pathogens across multiple patient populations with a variety of co-morbid conditions. INNA-051 antiviral efficacy is currently evaluated in a Phase 2a influenza-challenge conducted in healthy volunteers.

  • CODA-VAX H1N1: Codagenix

Codagenix has utilized a design platform to construct a live-attenuated, universal flu vaccine, CodaVax™-H1N1. The vaccine enables presentation of conserved antigens of the wild-type virus, demonstrating universal potential in primate models and thus the potential to provide multi-season protection when developed into its final quadrivalent formulation. Currently, it is being evaluated in Phase I stage of clinical trial evaluation to treat Influenza virus infections.

  • ALVR106: AlloVir

ALVR106 is an allogeneic, off-the-shelf, multi-virus specific VST therapy candidate designed to target diseases caused by the respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). In vitro data demonstrates that ALVR106 reactive cells have antiviral activity against each of the targeted viruses with minimal or no activity against non-virus-infected cells. This preclinical data supports the potential for antiviral benefit and safety of ALVR106 when administered to patients.

The Influenza Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Influenza with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Influenza Treatment.
  • Influenza Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Influenza Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Influenza market

Explore groundbreaking therapies and clinical trials in the Influenza Pipeline. Access DelveInsight’s detailed report now! @ New Influenza Drugs

Influenza Companies

Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc and others.

Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Influenza Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Unveil the future of Influenza Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Influenza Market Drivers and Barriers

Scope of the Influenza Pipeline Report

  • Coverage- Global
  • Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others.
  • Influenza Therapies- OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others
  • Influenza Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Influenza Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Influenza Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Influenza Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Influenza: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Influenza – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. mRNA-1010: Moderna
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. INNA-051: ENA Respiratory Pty Ltd
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. CODA-VAX H1N1: Codagenix
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Influenza Key Companies
  21. Influenza Key Products
  22. Influenza- Unmet Needs
  23. Influenza- Market Drivers and Barriers
  24. Influenza- Future Perspectives and Conclusion
  25. Influenza Analyst Views
  26. Influenza Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Dengue Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Dengue Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the Dengue pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dengue therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Dengue Research. Learn more about our innovative pipeline today! @ Dengue Pipeline Outlook

Key Takeaways from the Dengue Pipeline Report

  • In March 2025, AbViro LLC announced a phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Safety and Efficacy of 3 Dose Levels of AV-1 in Healthy Adults Challenged With a Controlled Human Infection Strain of DENV-3.
  • In March 2025, Takeda organized a study is to learn about TDV’s ability to create an immune response in adults, adolescents, and children administered. In this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first). During the study, participants will visit their study clinic 5 times.
  • In March 2025, Novartis Pharmaceuticals announced a study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
  • DelveInsight’s Dengue pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Dengue treatment.
  • The leading Dengue Companies such as Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
  • Promising Dengue Therapies such as EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.

Stay informed about the cutting-edge advancements in Dengue Treatments. Download for updates and be a part of the revolution in infectious disease care @ Dengue Clinical Trials Assessment

Dengue Emerging Drugs Profile

  • VIS 513: Visterra

VIS513, is a monoclonal antibody in development for the treatment of Dengue, a serious mosquito-borne virus, which in its most severe forms is characterized by uncontrolled bleeding leading to organ failure and death. VIS513 has in vitro and in vivo activity against all four Dengue virus serotypes found globally.

  • TAK-003: Takeda

Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses. Clinical Phase II data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants, which persisted through 48 months after vaccination, and the vaccine was found to be generally safe and well tolerated.

  • CDX DENV: Codagenix

Codagenix has leveraged the platform to re-design contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates. CDX DENV, is a Synthetic vaccine being developed in the Pre-Clinical stage for the treatment of Dengue.

  • AT 752: Atea Pharmaceuticals

AT-752, a diastomer of AT-527, is a novel purine nucleotide prodrug, designed to treat patients either newly infected or previously infected with the dengue virus. AT-752 has an favorable preclinical safety profile and has demonstrated potent in vitro activity against all dengue serotypes tested as well as potent antiviral activity in predictive animal models. Atea Pharmaceuticals plan to conduct clinical studies that will evaluate the daily administration of AT-752 over a short period of treatment, in order to negate the progression of infection and reduce the occurrence of life-threatening conditions associated with severe dengue.

The Dengue Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dengue with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Treatment.
  • Dengue Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dengue Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue market

Learn more about Dengue Drugs opportunities in our groundbreaking AL Dengue Research and development projects @ Dengue Unmet Needs

Dengue Companies

Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals and others.

Dengue pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Dengue Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Discover the latest advancements in Dengue Treatment by visiting our website. Stay informed about how we’re transforming the future of infectious disease @ Dengue Market Drivers and Barriers, and Future Perspectives

Scope of the Dengue Pipeline Report

  • Coverage- Global
  • Dengue Companies- Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
  • Dengue Therapies- EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.
  • Dengue Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Dengue Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Dengue Pipeline on our website @ Dengue Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Dengue: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Dengue– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. TAK-003: Takeda
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug Name: Company Name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AT 752: Atea Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Dengue Key Companies
  21. Dengue Key Products
  22. Dengue- Unmet Needs
  23. Dengue- Market Drivers and Barriers
  24. Dengue- Future Perspectives and Conclusion
  25. Dengue Analyst Views
  26. Dengue Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dengue Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Non Alcoholic Fatty Liver Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Non-Alcoholic Fatty Liver Disease Pipeline Insight 2025” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the Non Alcoholic Fatty Liver Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Non Alcoholic Fatty Liver Disease Pipeline. Dive into DelveInsight’s comprehensive report today! @ Non Alcoholic Fatty Liver Disease Pipeline Outlook

Key Takeaways from the Non Alcoholic Fatty Liver Disease Pipeline Report

  • In March 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
  • In March 2025, GlaxoSmithKline organized a study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.
  • In March 2025, AstraZeneca conducted a study is to investigate the safety, tolerability, and effects of increasing doses of AZD9550 in overweight and obese participants aged 18 through 65 years living with or without T2DM, and to investigate how AZD9550 is absorbed, distributed, and eliminated from the body.
  • DelveInsight’s Non Alcoholic Fatty Liver Disease pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for Non Alcoholic Fatty Liver Disease treatment.
  • The leading Non Alcoholic Fatty Liver Disease Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca and others.
  • Promising Non Alcoholic Fatty Liver Disease Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, and others.

Stay ahead with the most recent pipeline outlook for Non Alcoholic Fatty Liver Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non Alcoholic Fatty Liver Disease Treatment Drugs

Non Alcoholic Fatty Liver Disease Emerging Drugs Profile

  • Lanifibranor: Inventiva Pharma

Lanifibranor is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory, and beneficial metabolic changes in the body by activating each of the three PPAR isoforms, known as PPARα, PPARδ, and PPARɣ. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARɣ and partial activation of PPARɣ. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.

  • ZED 1227: Dr. Falk Pharma GmbH

ZED 1227, is a synthetic peptidomimetic compound designed by Zedira scientists to specifically inhibit the enzymatic activity of human tissue transglutaminase (TG2). Dr. Falk Pharma has acquired the licensing rights to ZED1227 in Europe and several non-European countries and has assumed responsibility for pharmaceutical, preclinical, and clinical development of the new chemical entity towards a pharmaceutical product. By inhibiting TG2 in liver tissue, ZED1227 is expected to improve liver fibrosis in patients with NAFLD. Currently the drug is in Phase II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.

  • TVB-2640: Sagimet Biosciences

TVB-2640 is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis. In addition to the FASCINATE-2 trial, denifanstat is being tested in a Phase III clinical trial for recurrent glioblastoma and a Phase II study for moderate to severe acne. Currently the drug is in Phase II stage of clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.

  • ALS-L1023: AngioLab

ALS L1023 is a dried extract of ethyl acetate, prepared by activity-guided fractionation from Melissa leaf (lemon balm). The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function. Currently the drug is in Phase II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.

  • AZD9550: AstraZeneca

AZD9550 is a GLP-1R glucagon dual agonist small molecule which is in early development for the treatment of NASH (non-alcoholic steatohepatitis), a type of liver disease that commonly affects overweight and obese patients who have T2DM. Currently the drug is in Phase I/II stage of its clinical trial for the treatment of Non-Alcoholic Fatty Liver Disease.

The Non Alcoholic Fatty Liver Disease Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non Alcoholic Fatty Liver Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Alcoholic Fatty Liver Disease Treatment.
  • Non Alcoholic Fatty Liver Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non Alcoholic Fatty Liver Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Alcoholic Fatty Liver Disease market

Explore groundbreaking therapies and clinical trials in the Non Alcoholic Fatty Liver Disease Pipeline. Access DelveInsight’s detailed report now! @ New Non Alcoholic Fatty Liver Disease Drugs

Non Alcoholic Fatty Liver Disease Companies

Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca and others.

Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Non Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Non Alcoholic Fatty Liver Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Non Alcoholic Fatty Liver Disease Market Drivers and Barriers

Scope of the Non Alcoholic Fatty Liver Disease Pipeline Report

  • Coverage- Global
  • Non Alcoholic Fatty Liver Disease Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca and others.
  • Non Alcoholic Fatty Liver Disease Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, and others.
  • Non Alcoholic Fatty Liver Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non Alcoholic Fatty Liver Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Non Alcoholic Fatty Liver Disease Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Non Alcoholic Fatty Liver Disease Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non-Alcoholic Fatty Liver Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non-Alcoholic Fatty Liver Disease – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Lanifibranor: Inventiva Pharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ZED 1227: Dr. Falk Pharma GmbH
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AZD9550: AstraZeneca
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Non-Alcoholic Fatty Liver Disease Key Companies
  21. Non-Alcoholic Fatty Liver Disease Key Products
  22. Non-Alcoholic Fatty Liver Disease – Unmet Needs
  23. Non-Alcoholic Fatty Liver Disease – Market Drivers and Barriers
  24. Non-Alcoholic Fatty Liver Disease – Future Perspectives and Conclusion
  25. Non-Alcoholic Fatty Liver Disease Analyst Views
  26. Non-Alcoholic Fatty Liver Disease Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non Alcoholic Fatty Liver Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Postpartum Depression Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Postpartum Depression Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the Postpartum Depression pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Postpartum Depression pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Postpartum Depression Pipeline. Dive into DelveInsight’s comprehensive report today! @ Postpartum Depression Pipeline Outlook

Key Takeaways from the Postpartum Depression Pipeline Report

  • In March 2025, Reunion Neuroscience Inc. announced a study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.
  • DelveInsight’s Postpartum Depression pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Diabetes treatment.
  • The leading Postpartum Depression Companies such as GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.
  • Promising Postpartum Depression Pipeline Therapies such as SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO® and others.

Stay ahead with the most recent pipeline outlook for Postpartum Depression. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Postpartum Depression Treatment Drugs

Postpartum Depression Emerging Drugs Profile

  • RE-104: Reunion Neuroscience

RE104 is a proprietary, potential best-in-class, serotonergic neuroplastogen. RE-104 is designed as a single-dose psychedelic that offers a fast onset and shorter treatment duration, as well as reproducible pharmacokinetics. It has potential across a variety of neuropsychiatric indications, including in PPD and AjD, where Reunion is focusing its initial clinical development efforts. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Postpartum Depression.

  • GH001: GH Research

GH001 is an inhaled formulation of mebufotenin (5-MeO-DMT), a psychedelic compound that acts as a potent serotonin 5-HT1A and 5-HT2A receptor agonist. By rapidly modulating serotonergic signaling, GH001 is believed to induce profound and short-lasting psychoactive effects, which may help reset dysfunctional neural circuits implicated in mood disorders. It is being investigated for treatment-resistant depression (TRD), bipolar II disorder, and postpartum depression.

  • BRII-297: Brii Bio

BRII-297 is a first-of-its-kind long-acting injectable (LAI) therapeutic candidate in development for the treatment of various anxiety and depressive disorders. Discovered internally, BRII-297 acts as a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator (PAM), a proven mechanism of action that is known to potentially restore “normal” levels GABAA receptor function for various depressive and anxiety central nervous system disorders. Currently, the drug is in Phase I stage of its clinical trial for the treatment of postpartum depression.

The Postpartum Depression Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Postpartum Depression with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postpartum Depression Treatment.
  • Postpartum Depression Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Postpartum Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Postpartum Depression market

Explore groundbreaking therapies and clinical trials in the Postpartum Depression Pipeline. Access DelveInsight’s detailed report now! @ New Postpartum Depression Drugs

Postpartum Depression Companies

GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.

Postpartum Depression Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Postpartum Depression Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Postpartum Depression Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Postpartum Depression Market Drivers and Barriers

Scope of the Postpartum Depression Pipeline Report

  • Coverage- Global
  • Postpartum Depression Companies- GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.
  • Postpartum Depression Pipeline Therapies- SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO® and others.
  • Postpartum Depression Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Postpartum Depression Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Postpartum Depression Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Postpartum Depression Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Postpartum Depression: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Postpartum Depression – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Postpartum Depression Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug Name: Company Name
  11. Mid Stage Products (Phase II)
  12. RE-104: Reunion Neuroscience
  13. Early Stage Products (Phase I)
  14. BRII-297: Brii Bio
  15. Pre-clinical and Discovery Stage Products
  16. Drug Name: Company Name
  17. Inactive Products
  18. Postpartum Depression Key Companies
  19. Postpartum Depression Key Products
  20. Postpartum Depression- Unmet Needs
  21. Postpartum Depression- Market Drivers and Barriers
  22. Postpartum Depression- Future Perspectives and Conclusion
  23. Postpartum Depression Analyst Views
  24. Postpartum Depression Key Companies
  25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Postpartum Depression Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies